作者
Volker Fischer, Alicia Rodríguez-Gascón, Francis Heitz, Ronald Tynes, Christian Hauck, Dalia Cohen, Alison EM Vickers
发表日期
1998/8/1
期刊
Drug Metabolism and Disposition
卷号
26
期号
8
页码范围
802-811
出版商
American Society for Pharmacology and Experimental Therapeutics
简介
The metabolism of valspodar (PSC 833; PSC), which is developed as a multidrug resistance-reversing agent, was investigated to assess the potential for drug-drug interactions and the pharmacological activity of major metabolites. The primary metabolites of PSC produced by human liver microsomes were monohydroxylated, as revealed by LC/MS. The major site of hydroxylation was at amino acid 9, resulting in M9, as determined by cochromatography with synthetic M9. Dihydroxylated and N-demethylated metabolites were also detected. PSC metabolism in two human livers exhibitedKM values of 1.3–2.8 μM. The intrinsic clearance was 9–36 ml/min/kg of body weight. PSC biotransformation was cytochrome P450 (CYP or P450) 3A dependent, based on chemical inhibition and on metabolism by Chinese hamster ovary cells expressing CYP3A. Ketoconazole was a competitive inhibitor (Ki = 0.01–0.04 μM). The …
引用总数
学术搜索中的文章
V Fischer, A Rodríguez-Gascón, F Heitz, R Tynes… - Drug Metabolism and Disposition, 1998